- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
AstraZeneca Has a Promising Oncology Pipeline
AstraZeneca's Phase III pipeline is growing ahead of plan, chief executive Pascal Soriot told a recent media briefing, and cancer drugs make up a major chunk of the pipeline.
AstraZeneca’s Phase III pipeline is growing ahead of plan, chief executive Pascal Soriot told a recent media briefing, and cancer drugs make up a major chunk of the pipeline.
In oncology, olaparib for solid tumours, moxetumomab pasudotox for hairy cell leukaemia and selumetinib for non-small cell lung cancer are expected to be key players. Also showing potential are AZD9291 a ‘third generation’ tyrosine kinase inhibitor for NSCLC, and from AstraZeneca’s biologics R&D arm MedImmune, MEDI4736, a PD-L1 monoclonal antibody that is being studied in patients with advanced solid tumours.
Within AZ’s oncology franchise, the breast cancer portfolio has been targeted for expansion and a raft of new combination therapies is under investigation,. However substantial growth is expected from established agents such as Faslodex (fulvestrant).
Read the full story at:
http://bit.ly/P1u39eSource: PharmaTimes
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Physician-Pharmacy Integration in Cancer Care: Pillars of Medically Integrated Pharmacy
December 16th 2025The foundation of medically integrated pharmacy includes 7 critical pillars. This commentary focuses on the benefits of 3 of those pillars: abandonment, adherence, and access/affordability.
Read More
